School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
Janssen Pharmaceutica, Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Int J Pharm. 2024 Mar 25;653:123902. doi: 10.1016/j.ijpharm.2024.123902. Epub 2024 Feb 14.
Three-dimensional printing (3DP) is an emerging technology, offering the possibility for the development of dose-customized, effective, and safe solid oral dosage forms (SODFs). Although 3DP has great potential, it does come with certain limitations, and the traditional drug manufacturing platforms remain the industry standard. The consensus appears to be that 3DP technology is expected to benefit personalized medicine the most, but that it is unlikely to replace conventional manufacturing for mass production. The 3DP method, on the other hand, could prove well-suited for producing small batches as an adaptive manufacturing technique for enabling adaptive clinical trial design for early clinical studies. The purpose of this review is to discuss recent advancements in 3DP technologies for SODFs and to focus on the applications for SODFs in the early clinical development stages, including a discussion of current regulatory challenges and quality controls.
三维打印(3DP)是一项新兴技术,为开发剂量定制、有效和安全的固体制剂(SODFs)提供了可能性。尽管 3DP 具有巨大的潜力,但它确实存在一定的局限性,传统的药物制造平台仍然是行业标准。共识似乎是,3DP 技术最有可能受益于个性化医疗,但不太可能取代传统制造技术用于大规模生产。另一方面,3DP 方法可能非常适合作为一种适应性制造技术,用于为早期临床研究的适应性临床试验设计提供支持,从而适合于生产小批量产品。本综述的目的是讨论 SODFs 中 3DP 技术的最新进展,并重点讨论 SODFs 在早期临床开发阶段的应用,包括对当前监管挑战和质量控制的讨论。